<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908335</url>
  </required_header>
  <id_info>
    <org_study_id>KAWIN-002-1</org_study_id>
    <nct_id>NCT01908335</nct_id>
  </id_info>
  <brief_title>A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C</brief_title>
  <official_title>Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Kawin Technology Share-Holding Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Kawin Technology Share-Holding Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This dose-escalating study is to evaluate the efficacy and the safety of different doses of a
      new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection
      (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic hepatitis C who have not been
      previously treated with Interferon(IFN) by exploring the dose-effect relationship, while
      identity the optimal dose for phase Ⅲ study. In addition, population pharmacokinetic method
      is adopted to assess the pharmacokinetic behavior, individuals / intra-individual
      variability, and the possible factors for further study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total 200 subjects will be randomized and enrolled into four groups proportionally receiving
      experimental drug of high dose, middle dose, low dose and positive-control drug. Treatment
      duration will be 24 or 48 weeks corresponding to different HCV genotype, genotype 2,3 and
      non-genotype2,3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cEVR (complete early virologic response)</measure>
    <time_frame>weeks 12 of study therapy</time_frame>
    <description>defined as the proportion of patients who had undetectable plasma HCV RNA at weeks 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who had undetectable plasma HCV RNA</measure>
    <time_frame>weeks 4, 24, 48 of study therapy and 24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA load reduction</measure>
    <time_frame>weeks 4, 12, 24, 48 of study therapy and 24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eRVR ( extended rapid virologic response)</measure>
    <time_frame>weeks 4 and 12 of study therapy</time_frame>
    <description>defined as the proportion of patients who had undetectable plasma HCV RNA at weeks 4 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breakthrough</measure>
    <time_frame>weeks 24, 48 of study therapy</time_frame>
    <description>defined as the proportion of patients who had detectable plasma HCV RNA at any point during treatment after virological response( undetectable plasma HCV RNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>12 and 24 weeks after the end of treatment</time_frame>
    <description>defined as the proportion of patients who had undetectable HCV RNA at the end of treatment, but reappearance of HCV RNA after then</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A (PEG-IFN-SA /RBV low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (PEG-IFN-SA /RBV middle dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (PEG-IFN-SA /RBV high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D (Pegasys /RBV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN-SA /RBV low dose</intervention_name>
    <description>24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3</description>
    <arm_group_label>A (PEG-IFN-SA /RBV low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN-SA /RBV middle dose</intervention_name>
    <description>24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3</description>
    <arm_group_label>B (PEG-IFN-SA /RBV middle dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN-SA /RBV high dose</intervention_name>
    <description>24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3</description>
    <arm_group_label>C (PEG-IFN-SA /RBV high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys /RBV</intervention_name>
    <description>24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3</description>
    <arm_group_label>D (Pegasys /RBV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18- 65 years

          -  Body Mass Index (BMI) 18-30

          -  Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year
             2004)

          -  Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive
             anti-HCV antibody

          -  Female subjects of childbearing age with no history of menopause and negative
             pregnancy test, both female and male( including their partners ) subjects were
             required to conduct adequate contraception since screening until the 6 months after
             treatment

          -  Volunteered to participate in this study, understood and signed an informed consent

        Exclusion Criteria:

          -  Previous IFN treated patients

          -  Co-infection with HAV, HBV, HEV, EBV, CMV and HIV

          -  Evidences of hepatic decompensation, including but not limited to serum total
             bilirubin&gt; 2 times the upper limit of normal (ULN); serum albumin &lt;35g/L; prothrombin
             activity (PTA) &lt;60%; ascites, upper gastrointestinal bleeding and hepatic
             encephalopathy; Child-Pugh score B/C grade

          -  Hepatotoxic drugs was used for a long time within past 6 months

          -  Diagnosed with primary hepatocellular carcinoma or supported by evidences including
             but not limited to AFP&gt; l00ng/ml, suspicious liver nodules by imaging examinations

          -  Liver diseases from causes other than HCV infection, including alcoholic liver
             disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis
             (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration
             (Wilson's disease) and hemochromatosis, etc.

          -  White blood cell count &lt;3×109/L; Neutrophil count&lt;1.5×109/L; platelet count&lt;90×109/L;
             hemoglobin below the lower limit of normal

          -  Serum creatinine not within the normal range

          -  Serum creatine kinase&gt; 3 ULN

          -  Positive thyroid antibodies (A-TPO, A-TG)

          -  Therapy with potent immunomodulatory agents such as adrenocorticotropic hormone,
             thymosin α1 etc. within past 6 months or an anticipated usage during the period of
             study

          -  Allergies or severe allergies, especially allergic to study drugs or any ingredients
             of the study drugs

          -  Severe autoimmune diseases; psychiatric and nervous system disorders, including
             history of Psychiatric illness or with family history (especially depression,
             depressive tendencies, epilepsy and hysteria, etc.); Serious blood disorders (all
             kinds of anemia, hemophilia, etc.); Severe kidney disease (chronic kidney disease,
             renal insufficiency, etc.); poorly controlled digestive diseases; endocrine disorders
             such as thyroid disease and diabetes; severe respiratory disease (pneumonia, chronic
             obstructive pulmonary disease, interstitial lung disease, etc.); cardiovascular
             diseases (hypertension, uncontrolled coronary atherosclerotic heart disease, heart
             failure, etc.); retinal disease; malignancies; or unsuitable for study considered by
             clinician

          -  Function organs transplant

          -  Evidence of alcohol or drug abuse (average alcohol consumption male&gt; 40g / day,
             female&gt; 20g / day)

          -  Pregnant or lactating women

          -  Usage of prohibition drugs in this study

          -  Participated in other clinical trials 3 months prior to the screening

          -  Unwilling to sign the informed consent and adhere to treatment requirements

          -  Other conditions not suitable for study judged by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng jun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Ditan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital Southern Medical Unbiversity</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The third people's hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital, Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College Huazhong University of Science ＆ Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union hospital, Tongji Medical College Huazhong University of Science ＆ Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central-South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu province hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of suzhou university</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yanbian University Hospital (Yanbian Hospital)</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Of Medical College of Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Of Medical College of Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital , , Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Infectious Disease Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong university</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Academy of Medical Science ＆Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Teaching Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xixi Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youyi Hospital, capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Beijing Military Region</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daping Hospital, Research Institute of Surgery Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijing Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Infectious Disease Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Kawin Technology Share-Holding Co., Ltd.</investigator_affiliation>
    <investigator_full_name>Cheng jun</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>interferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>virological response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

